This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Lurigethan | |
|---|---|
| Name | Lurigethan |
Lurigethan is a synthetic small molecule investigated as a pharmacological tool and potential therapeutic agent with activity across multiple receptor families and enzyme targets. First reported in preclinical studies, Lurigethan entered multidisciplinary interest among researchers in National Institutes of Health, European Medicines Agency, Food and Drug Administration, World Health Organization, and academic groups at institutions such as Harvard University, University of Oxford, Massachusetts Institute of Technology, Stanford University and University of Cambridge. Early literature links Lurigethan to investigations in fields involving Johns Hopkins University, Karolinska Institutet, ETH Zurich, University of Tokyo and industrial partners including Pfizer, Roche, Novartis and GlaxoSmithKline.
The trivial name Lurigethan was assigned in the original patent filings by inventors affiliated with Merck & Co. and collaborators at University College London, reflecting a systematic nomenclature process similar to those used by International Union of Pure and Applied Chemistry and World Health Organization Expert Committees. Trade and research names appeared in filings to United States Patent and Trademark Office, European Patent Office and communications to conferences such as American Chemical Society national meetings and the Society for Neuroscience annual conference. Nomenclature discussions referenced standards from International Nonproprietary Names and regulatory guidance from Medicines and Healthcare products Regulatory Agency.
Lurigethan is described as a heterocyclic, polyfunctional small molecule with defined stereocenters and multiple substituents typical of lead compounds reported in journals like Nature, Science, Cell, Journal of Medicinal Chemistry and Angewandte Chemie. Structural elucidation employed methods from X-ray crystallography, nuclear magnetic resonance spectroscopy, mass spectrometry and computational approaches used by groups at Max Planck Society and Lawrence Berkeley National Laboratory. Reported physicochemical properties include molecular weight, logP and pKa values consistent with drug-like space defined in publications from Lipinski and analytic standards from International Union of Pure and Applied Chemistry. Solid-state characterization referenced polymorphism studies similar to those in American Chemical Society publications and thermal analysis methods from Thermo Fisher Scientific research.
Synthetic routes to Lurigethan were disclosed in patents filed by teams at Merck & Co., Pfizer, Eli Lilly and Company and academic collaborators in protocols resembling methods taught at Massachusetts Institute of Technology and California Institute of Technology. Key steps use cross-coupling reactions inspired by work from Richard F. Heck, Akira Suzuki, Ei-ichi Negishi and asymmetric catalysis techniques from Nobel Prize in Chemistry laureates; protecting-group strategies cite protocols from R. B. Woodward-style retrosynthetic analysis taught at University of Chicago. Reported biosynthetic analogs and biotransformations were explored in microbial chassis studies similar to projects at Wageningen University, John Innes Centre and EMBL that emulate enzymatic steps characterized in studies from Salk Institute and The Rockefeller University.
Pharmacological profiling of Lurigethan indicates multi-target interactions with ligand-binding domains resembling those studied in G-protein-coupled receptor structural work from University of California, San Francisco and enzyme inhibition patterns comparable to inhibitors reported in Cell Chemical Biology and Nature Chemical Biology. In vitro assays referenced panels developed by National Cancer Institute, European Molecular Biology Laboratory and American Type Culture Collection and involved signaling pathways described in research from Howard Hughes Medical Institute, Broad Institute, Salk Institute and Cold Spring Harbor Laboratory. Pharmacokinetic and pharmacodynamic characterization drew on methodologies used by ClinicalTrials.gov-registered studies and modelling approaches from Simcyp and Physiologically Based Pharmacokinetic research groups, with comparative analyses to agents reported in Lancet and New England Journal of Medicine.
Preclinical studies proposed applications of Lurigethan in indications examined by consortia including Cancer Research UK, American Cancer Society, Alzheimer's Association, Michael J. Fox Foundation and Bill & Melinda Gates Foundation, with reported activity in cellular and animal models commonly used at Yale University, University of California, Los Angeles, Columbia University and University of Pennsylvania. Investigations explored translational pathways and clinical trial designs referenced by National Institutes of Health funding announcements and collaborative frameworks similar to those employed by European Commission Horizon projects, with exploratory uses in biomarker studies aligned to platforms at National Cancer Institute and National Institute of Mental Health.
Toxicology assessment followed guidelines from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and testing paradigms used by Organisation for Economic Co-operation and Development, Food and Drug Administration and European Medicines Agency safety evaluation programs. Preclinical safety signals were compared to historical controls from Centers for Disease Control and Prevention datasets and adverse-event frameworks in World Health Organization pharmacovigilance analyses; regulatory submissions referenced precedents set by approvals from European Commission and new-drug applications reviewed by Food and Drug Administration. Current status in many jurisdictions remains investigational with oversight by institutional review boards such as those at Johns Hopkins University and Massachusetts General Hospital.
Category:Pharmaceutical compounds